Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.

ABSTRACT:

Background

The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity.

Methods

We report findings in 23 patients who presented with thrombosis and thrombocytopenia 6 to 24 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca). On the basis of their clinical and laboratory features, we identify a novel underlying mechanism and address the therapeutic implications.

Results

In the absence of previous prothrombotic medical conditions, 22 patients presented with acute thrombocytopenia and thrombosis

SUBMITTER: Scully M 

PROVIDER: S-EPMC8112532 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature